Patrick Dumont
Research Subjects
Research Interests
Patrick Dumont has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Didier Debieuvre
Emile Muller Hospital, Mulhouse, France
3 shared publications - Alexis Benjamin Cortot
CNRS, Inserm, Institut Pasteur de Lille, UMR9020‐UMR1277‐Canther‐Cancer Heterogeneity, Plasticity and Resistance to Therapies, Univ. Lille CHU Lille Lille France
2 shared publications - Denis Moro-Sibilot
Thoracic Oncology Unit Teaching Hospital A Michallon, INSERM U823, Grenoble, France
2 shared publications Fabrice Barlesi
Aix-Marseille University, Assistance Publique Hopitaux de Marseille, Marseille, France
2 shared publicationsFrench Cooperative Thoracic Intergroup (IFCT)
2 shared publicationsGerard Zalcman
Centre Hospitalier Universitaire de Caen, Caen, France
2 shared publications
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 9003
IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.
9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be larger for continuation maintenance in pts with objective response (OR). This study assessed a maintenance strategy conditioned by response to cisplatin-gemcitabine (CG): continuation maintenance with G for pts with OR and switch maintenance with pemetrexed (P) for pts with SD compared with a control arm using P continuation maintenance following cisplatin-pemetrexed (CP) induction regimen. Methods: Eligibility criteria included age 18-70 years, PS of 0-1, untreated stage IV NSQ NSCLC without EGFR mutation or ALK rearrangement, ineligibility to bevacizumab. Pts were randomized 1:1 to receive either experimental CG arm: CG (4 cycles) followed by G maintenance in case of OR followed by second-line P or switch maintenance with P for pts with SD, or standard CP arm: 4 cycles CP induction regimen followed by maintenance P. Overall survival (OS) was the primary endpoint; secondary endpoints included PFS, response rate and safety. Results: Between Jul 2012 and Jun 2016, 932 pts were randomized (CG: 467, CP: 465). Pts characteristics were balanced between the arms. 255 pts (54.6%) in the CG arm received maintenance treatment (G: 142, P: 113) while 274 pts (58.9%) received P maintenance in the CP arm. Median number of maintenance cycles was 5 for G and 4 for P in both arms. The OS adjusted HR was 0.97 (95% CI 0.84, 1.13; p=0.72); median OS: 10.9m CG vs. 10.4m CP. The HR for PFS was 0.96 (95% CI 0.84, 1.10; p=0.56); median PFS: 5.0m CG vs. 4.7m CP. Safety profile was as expected during induction chemotherapy. During maintenance, grade ≥3 hematological AEs occurred in 28% and 31% of pts in CG and CP, respectively, with febrile neutropenia (2.4% vs. 1.1%), anemia (9.4% vs. 11.7%), thrombocytopenia (6.7% vs. 5.8%). No grade ≥3 non-hematological AEs occurred in >5% of pts except for asthenia (3.9% CG vs. 5.1% CP). Conclusions: Adapting maintenance strategy according to response to induction chemotherapy does not improve patient outcome. Clinical trial information: NCT01631136.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 9003
IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.
9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be larger for continuation maintenance in pts with objective response (OR). This study assessed a maintenance strategy conditioned by response to cisplatin-gemcitabine (CG): continuation maintenance with G for pts with OR and switch maintenance with pemetrexed (P) for pts with SD compared with a control arm using P continuation maintenance following cisplatin-pemetrexed (CP) induction regimen. Methods: Eligibility criteria included age 18-70 years, PS of 0-1, untreated stage IV NSQ NSCLC without EGFR mutation or ALK rearrangement, ineligibility to bevacizumab. Pts were randomized 1:1 to receive either experimental CG arm: CG (4 cycles) followed by G maintenance in case of OR followed by second-line P or switch maintenance with P for pts with SD, or standard CP arm: 4 cycles CP induction regimen followed by maintenance P. Overall survival (OS) was the primary endpoint; secondary endpoints included PFS, response rate and safety. Results: Between Jul 2012 and Jun 2016, 932 pts were randomized (CG: 467, CP: 465). Pts characteristics were balanced between the arms. 255 pts (54.6%) in the CG arm received maintenance treatment (G: 142, P: 113) while 274 pts (58.9%) received P maintenance in the CP arm. Median number of maintenance cycles was 5 for G and 4 for P in both arms. The OS adjusted HR was 0.97 (95% CI 0.84, 1.13; p=0.72); median OS: 10.9m CG vs. 10.4m CP. The HR for PFS was 0.96 (95% CI 0.84, 1.10; p=0.56); median PFS: 5.0m CG vs. 4.7m CP. Safety profile was as expected during induction chemotherapy. During maintenance, grade ≥3 hematological AEs occurred in 28% and 31% of pts in CG and CP, respectively, with febrile neutropenia (2.4% vs. 1.1%), anemia (9.4% vs. 11.7%), thrombocytopenia (6.7% vs. 5.8%). No grade ≥3 non-hematological AEs occurred in >5% of pts except for asthenia (3.9% CG vs. 5.1% CP). Conclusions: Adapting maintenance strategy according to response to induction chemotherapy does not improve patient outcome. Clinical trial information: NCT01631136.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9077
A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
9077 Background: Pemetrexed (Pem) + Cisplatine (Cis) + Bevacizumab (Bev) followed with maintenance therapy (Bev and/or Pem) is a therapeutic standard in advanced non-squamous NSCLC. Methods: A single arm phase II trial aimed to evaluate a stop and go strategy: Sequence 1: 3 cycles Pem 500 mg/m² + Cis 75 mg/m² + Bev 7.5 mg/kg q3 weeks, followed by maintenance Bev 7.5 mg/kg/3 week until progression ; sequence 2: reintroduction Pem + Cis + Bev, 3 cycles, Pem + Bev maintenance until progression. Primary endpoint: at least 75% of patients in the sequence 2 received the 3 cycles without cisplatin/carboplatin dose modification. Results: from Dec. 2012 to Aug. 2014, 120 patients (77 males) were included in 14 French hospitals: PS 0 (50%); median age 60.6 y (36.0 – 77.3). Of 113 eligible patients, 65 (57.5 %) were treated in sequence 2. 37 patients (56.9%, IC95% [45.1%-73.6%]) received the 3 cycles (sequence 2) at full dose; 86 % (n = 56) with or without dose reduction. At sequence 2, specific bev-induced grade 3 – 4 toxicity was reported in 7 (10.3%) patients (1 grade 5 haemoptysis). Median follow-up was 27.1m [24.7-29.6]. Secondary objectives showed a median Progression-Free Survival 1 (PFS1) (inclusion – progression 1) 5.8 m (IC95%:5.0 – 6.3); median PFS2 (progression 1 – progression 2) 6.6 m (IC95%:5.7 – 8.4); median duration of disease control (PFS1 + PFS 2) (n = 65) 11.4 m (IC95:10.1 – 13.4). Objective response rate after sequence 2 was 15.4% (IC95%: 6.6-24.2) with 60% of stable disease. The median overall survival for eligible population was 17.7 m (IC95% 13.1 – 21.6) and 20.5 m (16.9 – NR) for patients who reached the sequence 2 (n = 65). Conclusions: Although the stringent primary endpoint was not met, this study highlighted that a ‘stop and go’ strategy using a platinum-based chemotherapy with bevacizumab continuation beyond progression, compares favourably with standard schedule, deserving to be further studied in non-squamous advanced NSCLC. Clinical trial information: NCT01705184.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9077
A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
9077 Background: Pemetrexed (Pem) + Cisplatine (Cis) + Bevacizumab (Bev) followed with maintenance therapy (Bev and/or Pem) is a therapeutic standard in advanced non-squamous NSCLC. Methods: A single arm phase II trial aimed to evaluate a stop and go strategy: Sequence 1: 3 cycles Pem 500 mg/m² + Cis 75 mg/m² + Bev 7.5 mg/kg q3 weeks, followed by maintenance Bev 7.5 mg/kg/3 week until progression ; sequence 2: reintroduction Pem + Cis + Bev, 3 cycles, Pem + Bev maintenance until progression. Primary endpoint: at least 75% of patients in the sequence 2 received the 3 cycles without cisplatin/carboplatin dose modification. Results: from Dec. 2012 to Aug. 2014, 120 patients (77 males) were included in 14 French hospitals: PS 0 (50%); median age 60.6 y (36.0 – 77.3). Of 113 eligible patients, 65 (57.5 %) were treated in sequence 2. 37 patients (56.9%, IC95% [45.1%-73.6%]) received the 3 cycles (sequence 2) at full dose; 86 % (n = 56) with or without dose reduction. At sequence 2, specific bev-induced grade 3 – 4 toxicity was reported in 7 (10.3%) patients (1 grade 5 haemoptysis). Median follow-up was 27.1m [24.7-29.6]. Secondary objectives showed a median Progression-Free Survival 1 (PFS1) (inclusion – progression 1) 5.8 m (IC95%:5.0 – 6.3); median PFS2 (progression 1 – progression 2) 6.6 m (IC95%:5.7 – 8.4); median duration of disease control (PFS1 + PFS 2) (n = 65) 11.4 m (IC95:10.1 – 13.4). Objective response rate after sequence 2 was 15.4% (IC95%: 6.6-24.2) with 60% of stable disease. The median overall survival for eligible population was 17.7 m (IC95% 13.1 – 21.6) and 20.5 m (16.9 – NR) for patients who reached the sequence 2 (n = 65). Conclusions: Although the stringent primary endpoint was not met, this study highlighted that a ‘stop and go’ strategy using a platinum-based chemotherapy with bevacizumab continuation beyond progression, compares favourably with standard schedule, deserving to be further studied in non-squamous advanced NSCLC. Clinical trial information: NCT01705184.
- 1 January 2016
- Published by Elsevier in Lung Cancer
- Vol. 91, 1-6
The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart
- 1 January 2016
- Published by Elsevier in Lung Cancer
- Vol. 91, 1-6
The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart
- Open Access
- 27 June 2011
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 11 (1) , 183
Bacterial infection profiles in lung cancer patients with febrile neutropenia
The chemotherapy used to treat lung cancer causes febrile neutropenia in 10 to 40% of patients. Although most episodes are of undetermined origin, an infectious etiology can be suspected in 30% of cases. In view of the scarcity of data on lung cancer patients with febrile neutropenia, we performed a retrospective study of the microbiological characteristics of cases recorded in three medical centers in the Picardy region of northern France.
- 27 June 2011
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 11 (1) , 183
Open AccessBacterial infection profiles in lung cancer patients with febrile neutropenia
The chemotherapy used to treat lung cancer causes febrile neutropenia in 10 to 40% of patients. Although most episodes are of undetermined origin, an infectious etiology can be suspected in 30% of cases. In view of the scarcity of data on lung cancer patients with febrile neutropenia, we performed a retrospective study of the microbiological characteristics of cases recorded in three medical centers in the Picardy region of northern France.